Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 7

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  INTERLEUKIN-6
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Lactoferrin regulates production of interleukin-6 and tumor necrosis factor alpha in mice

100%
Machnicki M.
Postępy Higieny i Medycyny Doświadczalnej
|
1995
|
vol. 49
|
issue 1
53-57
2

Biology of interleukin-6 (IL-6) and its significance in the pathogenesis of some diseases

80%
Robak T.
Postępy Higieny i Medycyny Doświadczalnej
|
1994
|
vol. 48
|
issue 5
565-588
EN
In the paper numerous activities of IL-6 toward various normal and neoplastic cells are reviewed.The role of this cytokine in pathophysiology of various disease including infections and inflammatory and autoimmune diseases as well as in leukaemias, lymphomas and other neoplastic diseases is presented.Potential clinical value of the IL-6 levels in the serum and the role of its recombinant form in the treatment of thrombocytopenia and some neoplastic diseases is also discussed.
3

Pathogenic and diagnostic significance of IL-6 in rebal glomerular diseases

80%
Kacprzyk F.
Postępy Higieny i Medycyny Doświadczalnej
|
1995
|
vol. 49
|
issue 4
513-522
EN
IL-6 issynthetized by various types of cells and has multiple biological functions.In the kidney, IL-6 synthesized by mesangial cells and acts as an autocrine growth factor.Il-6 was demonstrated in the glomerular measangium and in teh urine of patients with proliferative glomerulonephritis, suggesting that it has an important role in the pathogenesis of renal glomerular diseases.
4

Interleukin 6, tumor necrosis factor alpha and their soluble receptors in the blood serum of patients with denture stomatitis and fungal infection

70%
Pietruski J. K., Pietruska M. D., Jablonska E., Sacha P., Zaremba M., Stokowska W.
|
|
vol. 48
|
issue 2
101-105
EN
Determinations of the blood serum levels of interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and their soluble receptors (sIL-6R, sTNFR) in denture stomatitis patients (DS) were performed. Serum levels of interleukins and their soluble receptors were measured using the ELISA method. In all examined patients mycological diagnostics were conducted using API 20C AUX stripe tests and an automatic ATB machine. Results were compared with those of healthy denture weares (D), and controls (C). In DS patients, yeasts were isolated in 90. 9%, in D in 66. 7% of cases. The most often isolated species in both groups was Candida albicans. Mean concentrations of IL-6 and TNF-alpha were statistically significantly higher in D and D groups compared to controls. Mean concentrations of sIL-6R were similar in all groups; however, concentrations of sTNFR in both DS and D groups were significantly lower compared to controls. There were no correlations found between values of IL-6 and TNF-alpha nor between examined interleukins and their soluble receptors.
5

Characterization of NO and cytokine release by transplantable melanoma cell lines in relationship to their differentiation

70%
Kozlowska K., Zarzeczna M., Cichorek M.
Archivum Immunologiae et Therapiae Experimentalis
|
2001
|
vol. 49
|
issue 2 suppl.
103
EN
Changes in the secretory activity of two transplantable melanoma lines (differing in many biological features) as regards nitric oxide (NO) and interleukin 6 (IL-6), tumor necrosis factor (TNF-), oncostatin M (OSM) secretion were the subject of the present study. Obtained results show that a spontaneous alteration of the hamster?s native melanoma line in to an amelanotic one is accompanied by a global change of the secretory activity but there was not distinct correlation between the endogenous cytokine secretion and NO secretion by cells of both melanoma lines.
6

The contribution of endotoxins present in the respiratory tract to overproduction of nitric oxide associated with impaired interleukin 6 release in bronchoalveolar leukocytes from lung cancer patients

61%
Cembrzynska-Nowak M., Bienkowska M., Werynska B., Dyla T., Jankowska R.
|
|
vol. 48
|
issue 2
119-125
EN
The purpose of the study was to assess the relation between the levels of endotoxins circulating in airways of patients with lung cancer and the ability of bronchoalveolar lavage (BAL) leukocytes for ex vivo release of nitric oxide (NO) and interleukin 6 (IL-6) and for in vitro lipopolysaccharide (LPS) -induced production of the mediators. Leukocytes isolated from the BAL of 11 patients and from 5 healthy individuals were cultured in the absence or presence of LPSE. coli. The levels of endotoxins in the BAL fluids (BALF) and the amounts of NO released ex vivo from unstimulated cells from the patients were highly (p = 0. 0025) elevated in comparison with those from healthy individuals. The release of NO was significantly correlated (Rs = 0. 638, p = 0. 047) with the levels of endotoxins in BALF. In contrast, production of IL-6 remained very low and a negative correlation (Rs = ?0. 623, p = 0. 0542) was observed between the amounts of NO and IL-6. It was also found that, in response to LPS, bronchoalveolar leukocytes from patients with lung cancer express a reduced capacity for in vitro production of NO and IL-6. Our data suggest that, in patients with lung cancer, the activation of BAL cells by endotoxins circulating in the airways may contribute, at least in part, to overproduction of spontaneous NO and, subsequently, the NO may reduce IL-6 production. Moreover, the exposure in vivo of the BAL cells to LPS renders them unable to respond to the second signals.
7

Human melanoma gene therapy: from animal studies to clinical trials

61%
Mackiewicz A., Kapcinska M., Laciak M., Malicki J., Murawa P., Nowak, Sibilska E., Wiznerowicz M., Breborowicz D., Lange A., Hawley R. G.
|
EN
Based on preclinical studies clinical protocol for immuno-gene therapy of human melanoma was designed in our Department.In January 1995, phase I clinical trial was initiated. Until now 5 patients with IV clinical degree of melanoma received geentic vaccine acco9rding to the following schedule: 4 injections in two weeks intervals, 3 injections in one month intervals and 3 injections in two month intervals.During therapy no toxic effects were observed.Induction of specific and non-specific anti-melanoma response was observed.Currently the trial enters phase II. Optimization of doses and immunization schedule as well as verification of patients eliglibility will be carried out.Moreover, clinical effcts of applied therapy will be monitored.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.